LRMR Stock Price, Larimar Therapeutics, . Quote, Chart

Market Summary

USD6.74+0.13

Delayedas of 30 Apr 2024, 01:05 pm

1.97%

LRMR Stock Price

View Fullscreen

LRMR RSI Chart

LRMR Valuation

Market Cap

421.7M

Price/Earnings (Trailing)

-11.41

Price/Sales (Trailing)

242.07

Price/Free Cashflow

-12.54

LRMR Price/Sales (Trailing)

LRMR Profitability

Return on Equity

-45.21%

Return on Assets

-38.51%

Free Cashflow Yield

-7.97%

LRMR Fundamentals

LRMR Revenue

Revenue (TTM)

2.3M

LRMR Earnings

Earnings (TTM)

-36.9M

Earnings Growth (Yr)

-37.86%

Earnings Growth (Qtr)

-43.35%

Breaking Down LRMR Revenue

52 Week Range

6.98

(Low)(High)

Last 7 days

3.3%

Last 30 days

-12.9%

Last 90 days

13.0%

Trailing 12 Months

39.8%

How does LRMR drawdown profile look like?

LRMR Financial Health

Current Ratio

9.49

LRMR Investor Care

Shares Dilution (1Y)

47.45%

Diluted EPS (TTM)

-0.84

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2019	2.3M	0	0	0
2018	1.0M	1.1M	1.5M	1.9M
2017	912.0K	934.0K	970.0K	996.0K
2016	608.0K	770.0K	857.0K	894.0K
2015	130.5K	233.0K	335.5K	438.0K
2014	0	0	0	28.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Larimar Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 16, 2024	flynn james e	bought	12,500,000	8.74	1,430,200	-
Feb 16, 2024	flynn james e	bought	12,500,000	8.74	1,430,210	-
Feb 14, 2024	thomas frank e	bought	22,000	11.00	2,000	-
Jan 17, 2024	shankar gopi	acquired	-	-	22,500	chief development officer
Jan 17, 2024	clayton russell	acquired	-	-	22,500	chief medical officer
Jan 17, 2024	ben-maimon carole	acquired	-	-	66,125	president and ceo
Jan 17, 2024	celano michael	acquired	-	-	31,250	chief financial officer
Dec 07, 2023	shankar gopi	bought	18,661	3.7323	5,000	chief development officer
May 17, 2023	ben-maimon carole	bought	18,525	3.705	5,000	president and ceo

Which funds bought or sold LRMR recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-11.36	210,757	651,033	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	new	-	462,000	462,000	-%
Apr 24, 2024	Solstein Capital, LLC	unchanged	-	13,610	33,980	0.02%
Apr 24, 2024	Assenagon Asset Management S.A.	new	-	4,828,640	4,828,640	0.01%
Apr 23, 2024	AMALGAMATED BANK	reduced	-61.33	-3,000	7,000	-%
Apr 23, 2024	Tennessee Valley Asset Management Partners	sold off	-100	-36.00	-	-%
Apr 23, 2024	BFSG, LLC	unchanged	-	6,080	15,180	-%
Apr 05, 2024	CWM, LLC	new	-	-	-	-%
Mar 11, 2024	VANGUARD GROUP INC	added	1.93	981,834	6,621,360	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	97.44	682,566	1,218,190	-%

Are Funds Buying or Selling LRMR?

Are funds buying LRMR calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own LRMR

No. of Funds

Unveiling Larimar Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 15, 2024	flynn james e	9.64%	6,151,389	SC 13D/A
Feb 26, 2024	ra capital management, l.p.	9.5%	6,045,351	SC 13G
Feb 16, 2024	flynn james e	10.07%	6,151,389	SC 13D/A
Feb 15, 2024	flynn james e	10.75%	4,721,183	SC 13D/A
Feb 14, 2024	blue owl capital holdings lp	7.78%	3,414,468	SC 13G
Feb 14, 2024	verition fund management llc	6.4%	2,811,131	SC 13G
Feb 14, 2024	perceptive advisors llc	0%	0	SC 13G/A
Feb 13, 2024	janus henderson group plc	6.0%	2,641,065	SC 13G/A
Aug 18, 2023	janus henderson group plc	5.1%	2,191,411	SC 13G
Mar 17, 2023	flynn james e	10.91%	4,721,183	SC 13D/A

Recent SEC filings of Larimar Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 29, 2024	ARS	ARS
Apr 29, 2024	DEF 14A	DEF 14A
Apr 12, 2024	PRE 14A	PRE 14A
Mar 15, 2024	SC 13D/A	13D - Major Acquisition
Mar 14, 2024	10-K	Annual Report
Mar 14, 2024	8-K	Current Report
Mar 14, 2024	S-8	Employee Benefits Plan
Mar 14, 2024	S-8	Employee Benefits Plan
Mar 11, 2024	8-K	Current Report
Feb 26, 2024	SC 13G	Major Ownership Report

Peers (Alternatives to Larimar Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	42.6B	6.8B	4.75%	-16.01%	-9.05	6.23	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.6B	1.8B	-1.40%	-26.02%	-42.16	10.15	76.23%	61.08%
BMRN	15.4B	2.5B	-5.97%	-14.48%	74.78	6.22	13.74%	186.89%
INCY	11.8B	3.7B	-7.74%	-29.36%	19.75	3.19	8.87%	75.42%
MID-CAP
APLS	5.8B	396.6M	-18.63%	-42.67%	-10.91	14.55	425.83%	18.94%
BBIO	4.5B	-	-17.63%	75.41%	-6.86	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-7.66%	3.02%	-14.59	12.9	440.80%	-27.84%
ARWR	2.9B	240.7M	-19.13%	-34.68%	-9.65	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-7.52%	-19.83%	-45.97	3.88	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.45%	-4.33%	25.14	4.51	85.90%	-14.05%
NVAX	600.4M	983.7M	-10.25%	-44.07%	-1.1	0.61	-50.36%	17.16%
CRBP	374.0M	881.7K	-9.17%	305.92%	-8.38	466.16	-77.61%	-5.33%
INO	268.8M	4.9M	-17.15%	24.46%	-1.99	55.23	-54.97%	51.71%
IBIO	5.8M	2.1M	-59.11%	53.70%	-0.21	2.14	-13.45%	66.37%

Larimar Therapeutics, Inc. News

Latest updates

Larimar Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																				(In Thousands)
Description	(%) Q/Q	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4	2017Q3	2017Q2	2017Q1	2016Q4	2016Q3	2016Q2	2016Q1	2015Q4	2015Q3	2015Q2	2015Q1	2014Q4	2014Q3	2014Q2
Revenue	-4.9%	642	675	623	324	267	256	266	247	227	230	230	225	209	193	143	63.00	39.00	26.00	14.00	1.00
Operating Expenses	-9.6%	13,277	14,691	15,169	15,560	15,702	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
S&GA Expenses	12.7%	3,646	3,234	3,339	3,351	3,269	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
R&D Expenses	-15.9%	9,631	11,457	11,830	12,209	12,433	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA Margin	0.1%	-61.27*	-61.31*	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	0.2%	500	499	475	466	458	8.00	31.00	53.00	73.00	97.00	132	140	160	180	200	213	213	212	213	443
EBT Margin	0%	-63.27*	-63.27*	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	67.6%	-4,724	-14,570	-15,067	-15,775	-15,956	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-7.7%	96.00	104	112	119	126	133	63.00	71.00	79.00	88.00	81.00	93.00	105	114	125	74.00	83.00	93.00	104	110	122
Current Assets	-8.4%	90.00	98.00	106	113	121	127	57.00	65.00	72.00	81.00	74.00	86.00	98.00	108	119	65.00	5.00	83.00	94.00	107	121
Cash Equivalents	-30.9%	27.00	39.00	94.00	112	27.00	86.00	20.00	63.00	70.00	72.00	71.00	62.00	68.00	101	113	39.00	1.00	43.00	37.00	36.00	49.00
Net PPE	13.8%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	1.00	1.00	0.00	0.00
Liabilities	26.5%	14.00	11.00	12.00	13.00	16.00	14.00	13.00	14.00	14.00	16.00	13.00	14.00	15.00	11.00	13.00	23.00	6.00	33.00	32.00	28.00	28.00
Current Liabilities	45.0%	10.00	7.00	7.00	8.00	11.00	9.00	8.00	9.00	9.00	10.00	8.00	8.00	9.00	5.00	7.00	10.00	6.00	16.00	13.00	14.00	13.00
Shareholder's Equity	-11.9%	82.00	93.00	100	106	111	119	50.00	57.00	64.00	72.00	68.00	79.00	90.00	103	113	2.00	54.00	2.00	1.00	1.00	3.00
Retained Earnings	-7.4%	-188	-175	-166	-158	-151	-142	-133	-125	-116	-107	-90.30	-77.70	-65.61	-51.41	-41.14	-399	-23.13	-389	-376	-364	-350
Additional Paid-In Capital	0.7%	270	268	266	264	262	261	184	182	181	179	158	156	155	154	154	451	22.00	449	448	446	444
Shares Outstanding	0.0%	44.00	44.00	43.00	43.00	43.00	22.00	18.00	18.00	18.00	18.00	16.00	16.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	80,219	-	-	-	21.00	-	-	-	94.00	-	-	-	123	-	-	-	40.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-1.6%	-9,343	-9,200	-7,365	-7,551	-6,672	-5,878	-7,486	-7,533	-7,918	-12,199	-10,782	-11,206	-9,857	-11,222	-12,199	-8,921	-7,911	-5,823	3,506	-12,471	-11,834
Share Based Compensation	5.3%	1,918	1,821	2,043	1,833	1,643	1,666	1,675	1,635	1,480	1,463	1,350	1,180	1,010	696	100	29.00	29.00	-1,021	100	2,076	2,290
Cashflow From Investing	94.3%	-2,629	-46,430	-9,838	92,250	-52,234	-3,384	-	-	6,490	-6,791	19,219	5,251	-23,545	-8.00	41,421	-778	-50.00	-	-840	807	14,267
Cashflow From Financing	-	-	-	-	-	-316	-	-	-	-	-	-	-	242	-135	83,903	9,577	3,455	9,950	5,895	95.00	1,757

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

LRMR Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 27,670	$ 24,250
General and administrative	14,088	12,276
Total operating expenses	41,758	36,526
Loss from operations	(41,758)	(36,526)
Other income (expense), net	4,809	1,171
Net loss	$ (36,949)	$ (35,355)
Net loss per share, basic	$ (0.84)	$ (1.37)
Net loss per share, diluted	$ (0.84)	$ (1.37)
Weighted average common shares outstanding, basic	43,901,241	25,761,394
Weighted average common shares outstanding, diluted	43,901,241	25,761,394
Comprehensive loss:
Net Income (Loss)	$ (36,949)	$ (35,355)
Other comprehensive loss:
Unrealized gain (loss) on marketable securities	112	(31)
Total other comprehensive gain (loss)	112	(31)
Total comprehensive loss	$ (36,837)	$ (35,386)

LRMR Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 26,749	$ 26,825
Marketable securities	60,041	91,603
Prepaid expenses and other current assets	3,385	2,311
Total current assets	90,175	120,739
Property and equipment, net	684	831
Operating lease right-of-use assets	3,078	2,858
Restricted cash	1,339	1,339
Other assets	659	638
Total assets	95,935	126,405
Current liabilities:
Accounts payable	1,283	1,686
Accrued expenses	7,386	8,408
Operating lease liabilities, current	837	611
Total current liabilities	9,506	10,705
Operating lease liabilities	4,709	4,797
Total liabilities	14,215	15,502
Commitments and contingencies (See Note 8)
Stockholders’ equity:
Preferred stock; $0.001 par value per share; 5,000,000 shares authorized as of December 31, 2023 and December 31, 2022; no shares issued and outstanding as of December 31, 2023 and December 31, 2022
Common stock, $0.001 par value per share; 115,000,000 shares authorized as of December 31, 2023 and December 31, 2022; 43,909,069 and 43,269,200 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively	43	43
Additional paid-in capital	270,150	262,496
Accumulated deficit	(188,554)	(151,605)
Accumulated other comprehensive gain (loss)	81	(31)
Total stockholders' equity	81,720	110,903
Total liabilities and stockholders' equity	$ 95,935	$ 126,405

About Larimar Therapeutics, Inc.

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is headquartered in Bala Cynwyd, Pennsylvania.

CEO	Dr. Carole S. Ben-Maimon M.D.
WEBSITE	larimartx.com
INDUSTRY	Biotechnology
EMPLOYEES	26

Larimar Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Larimar Therapeutics, Inc.? What does LRMR stand for in stocks?

LRMR is the stock ticker symbol of Larimar Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Larimar Therapeutics, Inc. (LRMR)?

As of Mon Apr 29 2024, market cap of Larimar Therapeutics, Inc. is 421.72 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LRMR stock?

You can check LRMR's fair value in chart for subscribers.

What is the fair value of LRMR stock?

You can check LRMR's fair value in chart for subscribers. The fair value of Larimar Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Larimar Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for LRMR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Larimar Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether LRMR is over valued or under valued. Whether Larimar Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Larimar Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LRMR.

What is Larimar Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 29 2024, LRMR's PE ratio (Price to Earnings) is -11.41 and Price to Sales (PS) ratio is 242.07. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LRMR PE ratio will change depending on the future growth rate expectations of investors.